Latest news with #RefleXion®X1
Associated Press
19-02-2025
- Business
- Associated Press
RefleXion Announces Executive Appointments
RefleXion Medical, a theranostic oncology company, today announced the appointment of Steve Schoch as chief financial officer (CFO) and the promotion of Phil Aulson to chief operating officer (COO). Both report to Todd Powell, RefleXion's president and chief executive officer. This press release features multimedia. View the full release here: RefleXion Medical appoints Steve Schoch as CFO. RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a groundbreaking treatment that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. (Photo: Business Wire) 'Steve's 30-year track record of excellence and diverse background will be a tremendous asset to the RefleXion team,' said Powell. 'He brings extensive experience in fundraising, financial infrastructure and operations management – critical components that will help RefleXion transition from an early-stage to a growth-stage commercial company.' Before joining RefleXion, Schoch served as COO and CFO at FLYR, Inc., a travel technology company, where he restructured global business and financial operations. Previously, he was CFO at 23andMe, where he led a nearly $1 billion equity raise, including the company's 2021 IPO. His executive tenure also includes roles at Miramax and Amgen. He currently serves as a board member and audit committee chair of Zura Bio, Ltd., a clinical-stage biotechnology company. Powell also announced Aulson's promotion to COO, highlighting his contributions during his nine-year tenure at RefleXion. 'Phil has been instrumental in developing our first factory, and establishing our manufacturing, operations, customer service and success teams,' said Powell. 'He is a proven leader who brings a strong focus on operational execution to RefleXion.' Aulson joined RefleXion in 2016 as director of new product introduction. His more than 25 years of experience in medical device manufacturing includes leadership roles at Fortune 500 and startup companies. Before joining RefleXion, he held executive and senior management positions at Oraya Therapeutics, Insound Medical, Hansen Medical, Boston Scientific, and Depuy/Johnson & Johnson. RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a groundbreaking treatment that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors and is being studied for broader indications. In addition, the company offers the RefleXion® X1 system for conventional radiotherapy for all solid tumors. Learn more at RefleXion Amy Cook [email protected] SOURCE: RefleXion Medical Copyright Business Wire 2025. PUB: 02/19/2025 10:01 AM/DISC: 02/19/2025 10:02 AM
Yahoo
10-02-2025
- Business
- Yahoo
RefleXion Expands Access to SCINTIX Therapy with First Freestanding Cancer Center
HAYWARD, Calif., February 10, 2025--(BUSINESS WIRE)--RefleXion Medical, a theranostic oncology company, today announced the scheduled installation of its RefleXion® X1 platform with SCINTIX® biology-guided radiotherapy at Beverly Hills Cancer Center (BHCC), the first freestanding cancer center (FSCC) that has installed the RefleXion X1. "At BHCC, we are committed to advancing cancer care by integrating the latest innovations, ensuring our patients receive the highest quality, cutting-edge treatments," said Arash (Ari) Gabayan, M.D., Chief of Radiation Oncology and Imaging at Beverly Hills Cancer Center. "We are excited to be amongst the first centers in the world to offer our patients this breakthrough technology, which uses the inherent biology of the patient's tumor to precisely direct the radiation beam to its tumor target. "This is a totally new and exciting concept in radiation treatment delivery, and we believe that using the tumor's own biology will transform how patients are treated," Dr. Gabayan continued. The RefleXion X1 machine with SCINTIX therapy is designed to use biology guidance to precisely treat one or more targets within the same treatment session. Early clinical cases have demonstrated that when the tumor moves, SCINTIX therapy autonomously shifts the radiation dose to follow the tumor, thereby safely delivering radiation to the tumor target while sparing radiation exposure to healthy tissue. "We are thrilled to count BHCC and its world-class cancer physicians among our early customers and as our first freestanding cancer center," said Todd Powell, president and CEO of RefleXion. "Their commitment to providing access to cutting-edge cancer treatments like SCINTIX therapy is invaluable." Beginning in 2025, the Centers for Medicare and Medicaid Services (CMS) will expand reimbursement for SCINTIX therapy, introducing new billing codes for FSCCs and professional reimbursement for physicians in both FSCCs and hospital outpatient departments. "We are encouraged that CMS has expanded reimbursement for freestanding cancer centers like BHCC as this supports clinicians who advance clinical adoption of new technologies and treatments," continued Powell. BHCC physicians consulted with Select Healthcare Solutions, a provider of turn-key medical technology solutions to independent physician groups, to integrate SCINTIX therapy into its comprehensive range of cancer treatment options. SCINTIX therapy uses signals emitted from a patient's cancer cells to direct radiation treatment. Patients receive an injection of a small amount of a unique molecule, called a PET tracer, which the cancer cells consume. The X1 detects the signals produced in real time and uses those to determine where to deliver the radiation dose. In contrast, conventional radiotherapy uses static images of anatomy to guide treatment delivery. About Beverly Hills Cancer Center Beverly Hills Cancer Center provides a unique model of exceptional care, integrating advanced clinical trials, cutting-edge diagnostics, and innovative treatments. With highly skilled physicians, a dedicated staff, and a tranquil healing environment, BHCC is recognized as a leading private cancer diagnostic and treatment facility in Southern California and beyond. Learn more at About RefleXion Medical RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a groundbreaking treatment that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors and is being studied for broader indications. In addition, the company offers the RefleXion® X1 system for conventional radiotherapy for all solid tumors. Learn more at View source version on Contacts Media Contacts: RefleXionAmy Cookacook@ Beverly Hills Cancer CenterSharon NemanSN@
